IR and HR of composite serious infections in tocilizumab initiators vs abatacept, propensity score-matched with a 1:1 fixed ratio
| Tocilizumab | Abatacept | HR (95% CI) | Rate difference† | |||||||
| Subjects (n) | Events | Person-years | IR* (95% CI) | Subjects (n) | Events | Person-years | IR (95% CI) | |||
| As-treated analysis | ||||||||||
| Medicare | 3850 | 230 | 3231 | 7.12 (6.20 to 8.04) | 3850 | 176 | 3659 | 4.81 (4.10 to 5.52) | 1.25 (1.06 to 1.47) | 2.31 (1.15, 3.47) |
| IMS | 3008 | 90 | 2688 | 3.35 (2.66 to 4.04) | 3008 | 54 | 2675 | 2.02 (1.48 to 2.56) | 1.58 (1.19 to 2.09) | 1.33 (0.45, 2.21) |
| MarketScan | 3556 | 68 | 2680 | 2.54 (1.93 to 3.14) | 3556 | 65 | 2760 | 2.36 (1.78 to 2.93) | 1.14 (0.85 to 1.54) | 0.18 (−0.65, 1.01) |
| Combined | 10 414 | 388 | 8599 | 4.51 (4.06 to 4.96) | 10 414 | 295 | 9094 | 3.24 (2.87 to 3.61) | 1.40 (1.20 to 1.63) | 1.27 (0.69, 1.85) |
| Intention-to-treat analysis up to 180 days | ||||||||||
| Medicare | 3850 | 157 | 1741 | 9.02 (7.61 to 0.43) | 3850 | 111 | 1752 | 6.34 (5.16 to 7.51) | 1.26 (1.03 to 1.55) | 2.68 (0.84, 4.52) |
| IMS | 3008 | 51 | 1376 | 3.71 (2.69 to 4.72) | 3008 | 32 | 1389 | 2.30 (1.51 to 3.10) | 1.34 (0.94 to 1.92) | 1.41 (0.12, 2.70) |
| MarketScan | 3556 | 44 | 1544 | 2.85 (2.01 to 3.69) | 3556 | 45 | 1552 | 2.90 (2.05 to 3.75) | 0.96 (0.67 to 1.37) | −0.05 (−1.24, 1.14) |
| Combined | 10 414 | 252 | 4661 | 5.41 (4.74 to 6.07) | 10 414 | 188 | 4693 | 4.01 (3.43 to 4.58) | 1.34 (1.11 to 1.63) | 1.40 (0.52, 2.28) |
*Incidence rate (IR) is per 100 person-years.
†Rate difference per 100 patients (tocilizumab-abatacept).